Indian company Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post.
The new formulation offers a cost-effective alternative to imported brands in the country.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.
The existing imported Hydroxyurea solution, which requires refrigeration between 2°C and 8°C, costs Rs77,000 ($928.9) in the Indian market.
Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients.
An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHydroxyurea aids red blood cells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body.
In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”
